Skip to main content
Premium Trial:

Request an Annual Quote

Highmark to Cover Biodesix's Veristrat Test

NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Highmark, a Blue Cross Blue Shield affiliate, for its Veristrat lung cancer test.

With the decision, Veristrat, which is intended to help guide second-line treatment in patients with advanced non-small cell lung cancer, gains access to Highmark's membership of 5.3 million people, the fourth-largest membership among BCBS-affiliated companies.

Veristrat uses MALDI mass spectrometry to measure plasma protein profiles of NSCLC patients with the aim of determining appropriate treatment for patients without epidermal growth factor receptor mutation or whose mutation status is unknown.

"Highmark's decision to cover VeriStrat enables a significantly larger patient population to benefit from the prognostic and predictive qualities of our proprietary test," Biodesix CEO David Brunel said in a statement.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.